Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Cancellation

27 Feb 2015 08:00

RNS Number : 0263G
Official List
27 February 2015
 



NOTICE OF CANCELLATION OF LISTING FROM THE OFFICIAL LIST

 

 

 

27/02/2015 8:00 AM

 

CANCELLATION

 

Ark Therapeutics Group Plc

 

The Financial Conduct Authority ("the FCA") cancels the securities set out below from the Official List effective from 27/02/2015 8:00 AM at the request of the company :

 

Ordinary Shares of 10p each

fully paid

Standard Shares 

(GB00BSZLMS59) ●

 

 

This notice has been issued by Listing Applications - 0207 066 8352.

 

Notes

 

- Notices issued by the FCA in respect of cancellation of securities from the Official List must be read in conjunction with notices issued by the relevant Recognised Investment Exchange.

 

● Denotes the security is also being cancelled from trading on the London Stock Exchange, a Recognised Investment Exchange.

- SEDOL numbers which are allocated by the London Stock Exchange as a Stock Exchange identifier may be found on their dealing notice.

 

† Denotes the security is also being cancelled from trading on ICAP Securities & Derivatives Exchange (ISDX), a Recognised Investment Exchange.

 

# Denotes the security is also being cancelled from trading on NYSE Euronext London, a Recognised Investment Exchange.

 

~ Denotes the security is also being cancelled from trading on BATS Europe Regulated Market, a Recognised Investment Exchange.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOTDQLFLELFZBBQ
Date   Source Headline
6th Jun 20122:41 pmRNSBlocklisting Interim Review
18th May 201212:02 pmRNSHolding(s) in Company
18th May 201212:01 pmRNSDirector Dealings
18th May 201211:57 amRNSResult of AGM
17th May 20127:00 amRNSInterim Management Statement
16th May 20127:00 amRNSCompletion of Phase 1 Study
2nd May 20127:00 amRNSGrant and Patent Update
25th Apr 20127:00 amRNSRegulatory Approval of Manufacturing Suite
17th Apr 20122:36 pmRNSDirector/PDMR Shareholding
10th Apr 20127:00 amRNSNew Board Appointment
2nd Apr 20123:25 pmRNSAnnual Information Update
26th Mar 20127:00 amRNSChange of Broker Name
15th Mar 20124:09 pmRNSDirector/PDMR Shareholding
13th Mar 20124:16 pmRNSBoard Changes
12th Mar 20127:00 amRNSFinal Results
23rd Feb 20124:29 pmRNSHolding(s) in Company
9th Feb 201211:10 amRNSNotice of Results
8th Feb 20127:00 amRNSUS patent for Neuropilin-1 receptor
4th Jan 20127:00 amRNSManufacturing Update
7th Dec 201111:48 amRNSDirector/PDMR Shareholding
5th Dec 20112:35 pmRNSBlocklisting Interim Review
9th Nov 20117:00 amRNSInterim Management Statement
3rd Nov 20117:00 amRNSManufacturing agreement
16th Sep 20114:41 pmRNSSecond Price Monitoring Extn
16th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20117:00 amRNSRe Agreement
24th Aug 20115:29 pmRNSHalf Yearly Report on National Storage Mechanism
24th Aug 20117:00 amRNSHalf Yearly Report - Part 2
24th Aug 20117:00 amRNSHalf Yearly Report - Part 1
1st Aug 20114:31 pmRNSHolding(s) in Company
29th Jul 20114:40 pmRNSSecond Price Monitoring Extn
29th Jul 20114:35 pmRNSPrice Monitoring Extension
25th Jul 20114:40 pmRNSSecond Price Monitoring Extn
25th Jul 20114:35 pmRNSPrice Monitoring Extension
18th Jul 20113:10 pmRNSHolding(s) in Company
14th Jul 20117:00 amRNSWins ?5.3 million EU Framework Programme 7 Grant
6th Jul 20117:00 amRNSArk receives Finnish Grants
4th Jul 20117:00 amRNSGrant of US patents and milestone payments
13th Jun 20114:40 pmRNSSecond Price Monitoring Extn
13th Jun 20114:35 pmRNSPrice Monitoring Extension
3rd Jun 201111:57 amRNSBlocklisting Interim Review
17th May 20117:00 amRNSInterim Management Statement
9th May 20113:28 pmRNSAGM Results
31st Mar 20111:43 pmRNSAnnual Information Update
30th Mar 20111:08 pmRNSDirector/PDMR Shareholding
24th Mar 20113:40 pmRNSAnnual Financial Report
9th Mar 20117:00 amRNSFinal Results
3rd Mar 20117:00 amRNSAppointment of CFO
2nd Mar 20117:00 amRNSDisposal
28th Feb 201111:49 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.